缺鐵性貧血市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、治療領域、最終用戶、地區和競爭細分，2020 年至 2030 年

2024 年全球缺鐵性貧血 (IDA) 市場價值為 51.4 億美元，預計到 2030 年將達到 75.9 億美元，預測期內複合年成長率為 6.68%。作為更廣泛的醫療保健領域中的關鍵部分，缺鐵性貧血在全球不同年齡層和人群中廣泛流行，因此，IDA 市場具有複雜性和日益成長的重要性。

該市場涵蓋廣泛的診斷解決方案、治療方法和支持性護理產品，旨在解決 IDA 的多面性。人們對這種疾病及其潛在的健康後果的認知不斷提高，是推動市場成長的主要催化劑。隨著全球醫療保健體系的發展和醫療服務可近性的改善，早期篩檢和診斷率正在上升，對創新治療方案的需求也隨之增加。作為回應，製藥公司和醫療保健提供者正在大力投資研發，以提高診斷能力和治療干預措施。

關鍵市場促進因素

全球缺鐵性貧血盛行率不斷上升

主要市場挑戰

經濟不平等和醫療保健機會有限

克服這些挑戰需要有針對性的政策干預、擴大醫療保健資金以及讓所有人群平等獲得負擔得起的診斷和治療。

主要市場趨勢

治療方案的創新與多樣化

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球缺鐵性貧血市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（口服鐵劑治療、腸外鐵劑治療、紅血球輸注、其他）
  • 依治療領域（婦產科、腫瘤科、充血性心臟衰竭 (CHF)、發炎性腸道疾病、腎臟科、其他）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按治療類型
  • 按治療領域
  • 按最終用戶
  • 按地區

第5章：亞太地區缺鐵性貧血市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按治療類型
  • 按治療領域
  • 按最終用戶
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲缺鐵性貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美缺鐵性貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
  • 治療類型
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第8章：南美洲缺鐵性貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第9章：中東和非洲缺鐵性貧血市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 12 章：全球缺鐵性貧血市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

第 15 章：策略建議

第16章調查會社について,免責事項

Global Iron deficiency anemia (IDA) market was valued at USD 5.14 billion in 2024 and is projected to reach USD 7.59 billion by 2030, growing at a CAGR of 6.68% during the forecast period. As a key segment within the broader healthcare landscape, the IDA market is defined by its complexity and growing significance, given the widespread prevalence of iron deficiency anemia across diverse age groups and populations globally.

This market encompasses a broad spectrum of diagnostic solutions, therapeutic treatments, and supportive care products designed to address the multifaceted nature of IDA. Increased awareness surrounding the condition, along with its potential health consequences, is a major catalyst driving market growth. As global healthcare systems evolve and access to medical services improves, early screening and diagnosis rates are rising-resulting in greater demand for innovative treatment options. In response, pharmaceutical companies and healthcare providers are significantly investing in research and development to advance diagnostic capabilities and therapeutic interventions.

Key Market Drivers

Increasing Global Prevalence of Iron Deficiency Anemia

The escalating prevalence of IDA is one of the most significant growth drivers for the global market. Iron deficiency anemia continues to represent a major global health challenge, impacting individuals across all demographics.

Shifts in dietary habits are a key contributor. Modern diets often lack sufficient iron-rich foods, such as red meats and leafy greens, and are increasingly reliant on processed or nutrient-deficient alternatives. The growing adoption of vegetarian and vegan diets, while beneficial for various reasons, may lack heme iron-a form more readily absorbed by the body-further heightening the risk of deficiency. This has fueled demand for iron supplements, fortified foods, and other nutritional solutions.

Additionally, the rising incidence of chronic health conditions has increased vulnerability to IDA. Gastrointestinal disorders such as inflammatory bowel disease and celiac disease can inhibit iron absorption, while chronic inflammation can limit iron availability for red blood cell production. As these underlying health issues become more widespread, the need for effective IDA diagnostics and treatments continues to grow.

Key Market Challenges

Economic Inequality and Limited Access to Healthcare

Despite being a global concern, iron deficiency anemia disproportionately affects individuals in low-income and underserved regions due to economic and healthcare disparities. These disparities present considerable obstacles to diagnosis, treatment, and overall disease management.

In many developing countries, access to basic medical services remains limited. Regular health screenings and affordable diagnostic testing are often unavailable, resulting in delayed or missed diagnoses. Even when symptoms are recognized, financial constraints frequently prevent individuals from seeking care or purchasing prescribed treatments.

The affordability and consistent availability of iron supplements-a cornerstone of IDA management-pose an additional challenge. In rural or resource-limited settings, these products may be prohibitively expensive or entirely inaccessible. Vulnerable groups, including pregnant women, infants, and children, are particularly affected, with untreated IDA leading to complications such as preterm birth and developmental delays.

Overcoming these challenges requires targeted policy interventions, expanded healthcare funding, and equitable access to affordable diagnostics and treatments across all population segments.

Key Market Trends

Innovation and Diversification in Treatment Options

Ongoing advancements in IDA treatment have significantly diversified and strengthened the global market. While traditional iron supplements-available in oral, liquid, and intravenous forms-remain central to care, new formulations are improving bioavailability and reducing adverse side effects, thus enhancing patient adherence and outcomes.

Innovative treatments such as erythropoiesis-stimulating agents (ESAs) have transformed the management of moderate to severe anemia. These therapies promote red blood cell production, reducing reliance on blood transfusions and offering a more sustainable, patient-friendly option.

Moreover, targeted therapies are emerging to address specific underlying causes of iron deficiency. For example, patients with gastrointestinal disorders that limit iron absorption now have access to specialized treatments designed to optimize iron uptake and utilization. This personalized approach not only improves treatment efficacy but also expands the market by accommodating the diverse clinical needs of the patient population.

Pharmaceutical firms and healthcare organizations continue to invest in research and innovation, enhancing the overall ecosystem for IDA management. This evolution of therapeutic offerings is broadening the market's reach and solidifying its long-term growth potential.

Key Market Players

• Daiichi Sankyo Company
• Novartis AG
• Rockwell Medical Inc
• Iron4u Aps
• AbbVie Inc
• Sanofi
• Disc Medicine Inc
• Pfizer Inc
• Akebia Therapeutics
• Keros Therapeutics Inc

Report Scope:

In this report, the Global Iron Deficiency Anemia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Iron Deficiency Anemia Market, By Therapy Type:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion
• Others

Iron Deficiency Anemia Market, By Therapy Areas:

• Obstetrics and Gynecology
• Oncology
• Congestive Heart Failure (CHF)
• Inflammatory Bowel Disease
• Renal
• Others

Iron Deficiency Anemia Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Iron Deficiency Anemia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Iron Deficiency Anemia Market.

Available Customizations:

Global Iron Deficiency Anemia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Iron Deficiency Anemia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Therapy Type (Oral Iron Therapy, Parenteral Iron Therapy, Red Blood Cell Transfusion, Others)
  • 4.2.2. By Therapy Areas (Obstetrics and Gynecology, Oncology, Congestive Heart Failure (CHF), Inflammatory Bowel Disease, Renal, Others)
  • 4.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Therapy Type
  • 4.3.2. By Therapy Areas
  • 4.3.3. By End User
  • 4.3.4. By Region

5. Asia Pacific Iron Deficiency Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type
  • 5.2.2. By Therapy Areas
  • 5.2.3. By End User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Iron Deficiency Anemia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Therapy Type
      • 5.3.1.2.2. By Therapy Areas
      • 5.3.1.2.3. By End User
  • 5.3.2. India Iron Deficiency Anemia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Therapy Type
      • 5.3.2.2.2. By Therapy Areas
      • 5.3.2.2.3. By End User
  • 5.3.3. Australia Iron Deficiency Anemia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Therapy Type
      • 5.3.3.2.2. By Therapy Areas
      • 5.3.3.2.3. By End User
  • 5.3.4. Japan Iron Deficiency Anemia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Therapy Type
      • 5.3.4.2.2. By Therapy Areas
      • 5.3.4.2.3. By End User
  • 5.3.5. South Korea Iron Deficiency Anemia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Therapy Type
      • 5.3.5.2.2. By Therapy Areas
      • 5.3.5.2.3. By End User

6. Europe Iron Deficiency Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Therapy Areas
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Iron Deficiency Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Therapy Areas
      • 6.3.1.2.3. By End User
  • 6.3.2. Germany Iron Deficiency Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Therapy Areas
      • 6.3.2.2.3. By End User
  • 6.3.3. Spain Iron Deficiency Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Therapy Areas
      • 6.3.3.2.3. By End User
  • 6.3.4. Italy Iron Deficiency Anemia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy Type
      • 6.3.4.2.2. By Therapy Areas
      • 6.3.4.2.3. By End User
  • 6.3.5. United Kingdom Iron Deficiency Anemia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy Type
      • 6.3.5.2.2. By Therapy Areas
      • 6.3.5.2.3. By End User

7. North America Iron Deficiency Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Therapy Type
  • 7.2.2. Therapy Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Iron Deficiency Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Therapy Areas
      • 7.3.1.2.3. By End User
  • 7.3.2. Mexico Iron Deficiency Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Therapy Areas
      • 7.3.2.2.3. By End User
  • 7.3.3. Canada Iron Deficiency Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Therapy Areas
      • 7.3.3.2.3. By End User

8. South America Iron Deficiency Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Therapy Areas
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Iron Deficiency Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Therapy Areas
      • 8.3.1.2.3. By End User
  • 8.3.2. Argentina Iron Deficiency Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Therapy Areas
      • 8.3.2.2.3. By End User
  • 8.3.3. Colombia Iron Deficiency Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Therapy Areas
      • 8.3.3.2.3. By End User

9. Middle East and Africa Iron Deficiency Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Therapy Areas
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Iron Deficiency Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Therapy Areas
      • 9.3.1.2.3. By End User
  • 9.3.2. Saudi Arabia Iron Deficiency Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Therapy Areas
      • 9.3.2.2.3. By End User
  • 9.3.3. UAE Iron Deficiency Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Therapy Areas
      • 9.3.3.2.3. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Iron Deficiency Anemia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Daiichi Sankyo Company
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Rockwell Medical Inc
• 14.4. Iron4u Aps
• 14.5. AbbVie Inc
• 14.6. Sanofi
• 14.7. Disc Medicine Inc
• 14.8. Pfizer Inc
• 14.9. Akebia Therapeutics
• 14.10.Keros Therapeutics Inc

15. Strategic Recommendations

16. About Us & Disclaimer